Nanna LüneborgPartner at Novo Ventures
Nanna Lüneborg is a Partner with Novo Ventures, a leading life science firm with offices in Copenhagen, London, Boston and San Francisco, and part of Novo Holdings. She joined Novo Holdings in 2012. Previously, she was an associate at Apposite Capital, a London-based venture fund. Dr. Lüneborg holds a first-class B.A. in Physiology and Psychology from the University of Oxford, a M.B.A. with distinction from University of Cambridge, where she was a Sainsbury Scholar, and a Ph.D. in Neuroscience from University College London, where she was as a Wellcome Trust Scholar. She has worked with numerous portfolio companies from company creation through multiple venture rounds and IPOs, including Orphazyme, ObsEva, IO Biotech and Galecto. She currently serves on the boards of ReViral, Stargazer and E3 Bio.